Skip to main content
. 2013 Spring;13(1):91–99.

Figure 2.

Figure 2.

Ad-K5 vs Ad-RSV-LacZ virus treatment of neuroblastoma cells. INSM1-negative (A) SK-N-SH (neuroblastoma) and (B) HepG2 (hepatocellular carcinoma) and INSM1-positive (C) IMR-32 (neuroblastoma) and (D) SK-N-BE(2) (neuroblastoma) were seeded at 5,000-10,000 cells/well in a 96-well dish and transduced with multiplicity of infection 0, 10, 25, 50, 100, and 200 of Ad-RSV-LacZ (negative control) and Ad-K5 virus. Twenty-four hours post–virus transduction, the cells were treated with 100 μM ganciclovir. The cells were incubated an additional 5 days and assayed for viability using the CellTiter-Glo assay. The graphs represent the average of 2 experiments performed in triplicate.